|1.||Pevzner, D V: 2 articles (01/2010 - 05/2004)|
|2.||Mazurov, A V: 2 articles (01/2010 - 05/2004)|
|3.||Samko, A N: 1 article (01/2010)|
|4.||Frolova, N S: 1 article (01/2010)|
|5.||Staroverov, I I: 1 article (01/2010)|
|6.||Ruda, M Ya: 1 article (01/2010)|
|7.||Vlasik, T N: 1 article (05/2004)|
|8.||Ruda, M Ia: 1 article (05/2004)|
|1.||Acute Coronary Syndrome
01/01/2010 - "Efficacy and safety of monafram in primary coronary angioplasty of patients with acute coronary syndrome without ST segment elevation (non ST ACS) was evaluated in this study. "
01/01/2010 - "[Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation]."
|2.||Myocardial Ischemia (Ischemic Heart Diseases)
01/01/2010 - "Within 30 days of follow up period monafram decreased by more than 2.5 fold the total amount of unfavorable outcomes (cardiovascular death, myocardial infarction and indications for repeat revascularization due to angina recurrence) - from 19.2% to 7.4% (p<0.001). "
05/01/2004 - "Within one month after coronary angioplasty Monafram decreased the number of end points (fatal and nonfatal myocardial infarction and angina recurrence) from 11.4 to 3.3%."
|1.||Angioplasty (Angioplasty, Transluminal)